Biaxin Transition: XL Accounts For 65% Of Franchise Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Biaxin XL (extended-release clarithromycin) accounts for approximately 65% of sales of the Biaxin franchise, Abbott said Jan. 18
You may also be interested in...
Abbott Reaches Settlement With Teva On Biaxin XL
Abbott is not releasing the terms of the agreement and said it is pursuing a lawsuit against Andrx.
Abbott Reaches Settlement With Teva On Biaxin XL
Abbott is not releasing the terms of the agreement and said it is pursuing a lawsuit against Andrx.
Abbott To Bolster Biaxin XL Patent Protection Ahead Of Compound Expiration In May
The additional intellectual property for the extended-release formulation will give generic firms “something to think about,” Abbott CFO Freyman says at SG Cowen investor conference. Abbott says it filed suit against three generic manufacturers March 14.